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Background
Overexpression of microRNA-31 (miR-31) is implicated in the pathogenesis of esophageal
squamous cell carcinoma (ESCC), a deadly disease associated with dietary zinc-deficiency. Using
a rat model that recapitulates features of human ESCC, the mechanism whereby Zn regulates
miR-31 expression to promote ESCC is examined.

Methods
To inhibit in vivo esophageal miR-31 overexpression in Zn-deficient rats (n = 12-20 per group),
locked-nucleic-acid modified anti-miR-31 oligonucleotides were administered over 5weeks. miR-31 expression was determined by northern blotting, qPCR, and in situ hybridization.
Physiological miR-31 targets were identified by microarray analysis and
verified by luciferase reporter assay. Cellular proliferation, apoptosis, and expression of
inflammation genes were determined by immunoblotting, caspase assays, and
immunohistochemistry. The miR-31 promoter in Zn-deficient esophagus was identified by ChIPseq using an antibody for histone mark H3K4me3. Data were analyzed with t-test and ANOVA. All
statistical tests were two-sided.

Results
In vivo, anti-miR-31 reduced miR-31 overexpression (P =.002) and suppressed the esophageal
preneoplasia in Zn-deficient rats. At the same time, the miR-31 target Stk40 was derepressed,
thereby inhibiting the STK40-NF-kB controlled inflammatory pathway, with resultant decreased
cellular proliferation and activated apoptosis (caspase 3/7 activities, fold change = 10.7, P = .005)..
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This same connection between miR-31 overexpression and STK40/NF-kB expression was also
documented in human ESCC cell lines. In Zn-deficient esophagus, the miR-31 promoter region
and NF-kB binding site were activated. Zn-replenishment restored the regulation of this genomic
region and a normal esophageal phenotype.
Conclusions
The data define the in vivo signaling pathway underlying interaction of Zn-deficiency and miR31 overexpression in esophageal neoplasia and provide a mechanistic rationale for
miR-31 as a therapeutic target for ESCC.
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Introduction
Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer death worldwide (1).
Due to lack of early symptoms, ESCC is typically diagnosed at an advanced stage, and only 10%
of patients survive 5-years. Thus, clarification of the mechanisms underlying the pathogenesis of
ESCC and development of new prevention and therapeutic strategies are urgently needed.
MicroRNAs (miRNAs) are short, non-coding RNAs that regulate gene expression by means of
translational inhibition and mRNA degradation (2). Each miRNA has the ability to inhibit multiple
target genes or entire signaling pathways, regulating a range of biological processes, including cell
proliferation, differentiation, and apoptosis. MiRNA expression levels are altered in all human
cancers studied (3). MiRNAs can act as oncogenes or tumor suppressors (4, 5) and have emerged
as therapeutic targets for cancer (6). The challenge is to identify their protein targets and
determine how these protein targets contribute to tumor initiation and progression.
Risk factors for ESCC include alcohol and tobacco use and known nutritional factors such as
Zn-deficiency (7). Our well-characterized Zn-deficient (ZD) rat esophageal cancer model
reproduces the ZD (7) and inflammation feature of human ESCC (8) and is exquisitely sensitive to
esophageal tumorigenesis by environmental carcinogens (9, 10). We have previously shown that
rats on a ZD diet for 5 weeks develop hyperplastic esophagi with a distinct gene signature that
includes upregulation of the proinflammation mediators S100a8/a9 (11). Prolonged ZD (23 weeks)
leads to an expanded cancer-associated inflammatory program (10) and induction of an oncogenic
miRNA signature with miR-31 as the top upregulated species (12), as also observed in human
ESCCs (13, 14).
miR-31 is among the most frequently dysregulated microRNAs in human cancers (15).
Depending on tumor type, miR-31 can be up- or downregulated, thus exhibiting oncogenic or
tumor suppressive roles in cancers. Notably, miR-31 is overexpressed and oncogenic in colorectal
cancer (16), lung cancer (17), and squamous cell carcinomas (SCCs), including ESCC (13, 14),
tongue SCC (18), head and neck SCC (19), and skin SCC (20), but it is downregulated in serous
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ovarian cancer (21). , The mechanisms by which miR-31 upregulation contributes to ESCC
initiation and progression are not understood. In the present study, the biological functions of miR31 in esophageal neoplasia and the mechanism whereby Zn regulates miR-31 expression to
promote ESCC were examined.

Methods
Animals Studies
Animal protocols were approved by the Thomas Jefferson University Animal Care and Use
Committee. Weanling male Sprague-Dawley rats were from Taconic Laboratory. Customformulated ZD and ZS diets (Harlan Teklad, Madison, WI) were identical except for the amount
of zinc, which was 3-4 ppm for ZD and 60 ppm for ZS diet. Further details on animal studies,
tissue isolation; RNA preparation; RT-QPCR; TaqMan miRNA assay; enzyme-linked
immunosorbent assay; western blot, northern blot, caspase, luciferase, cell proliferation, and
electrophoretic mobility shift assays; in situ hybridization (ISH); immunohistochemistry; and
serum Zn measurement are in Supplementary Methods, available online.
Locked-Nucleic Acid (LNA)-Modified Oligonucleotides
Custom

unlabeled

and

phosphothioated

LNATM

anti-rno-miR-31

oligonucleotide

(5’-

CAGCTATGCCAGCATCTTGCCT-3’, complementary to nucleotides 1-22 in the mature miR-31
sequence)

and

control

rno-miR-31

scrambled

oligonucleotide

(5’-

GTGTAACACGTCTATACGCCCA-3’) were obtained from Exiqon (Vedbaek, Denmark).

Human ESCC Samples and Cell Lines
Twelve cases of formalin-fixed paraffin-embedded (FFPE) human ESCC samples were
obtained from Thomas Jefferson University Hospital, Philadelphia, PA, USA. Human ESCC cell
lines (KYSE-series) that were established from primary ESCC tumors (22) were purchased from
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German Collection of Microorganisms and Cell Cultures. Human esophagus Het-1A was from
American Type Culture Collection (ATCC). The cells were cultured in RPMI 1640 (Life
Technologies) with 5% fetal bovine serum at 37oC with 5% CO2.
miRNA and mRNA Expression Profiling and Analyses
The Ohio State University custom miRNA microarray chips (OSU_CCC version 3.0) and
Affymetrix Rat Genome 230 2.0 GeneChip (Affymetrix), respectively. See Supplementary
Methods for details. The ArrayExpress accession numbers for miRNA and mRNA expression
profiling are E-MTAB-2208 and E-MTAB-2315, respectively
ChIP-sequencing
The ChIP reaction was performed at Active Motif (Carlsbad, CA), as detailed in Supplementary
Methods. Briefly, an aliquot of esophageal chromatin (30 μg) was precleared with protein A
agarose beads (Invitrogen). DNA was immune-precipitated with anti-H3K4me1 (Active Motif,
39297, Lot.1), anti-H3K4me3 (Active Motif, 39159 Lot.4), or anti-H3K27me3 (Millipore 07-449,
Lot. JBC1854858). ChIP sequencing at 50 bp single end (approximately 40M reads/sample)
was performed on Illumina HiSeq 2000 at HudsonAlpha Genomic Service Laboratory
(Huntsville, Alabama).
Peak Calling and Data Analysis
Details are given in Supplementary Methods. Briefly, the collection of aligned reads were filtered
to remove artifacts and mapped to the rat genome (rn4) using the Bowtie (23) algorithm. The
number of uniquely mapped monoclonal reads for each ChIP-seq group is shown in
Supplementary Table 4. To identify enriched regions of histone modifications ChIP-seq data,
peak calling was performed using 0 algorithm (24).
MOTIF-Finding and Quality Control
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To find TFBs, we used rat genome (rn4) and Jaspar (25) and TRANSFAC database (26).
Further details are given in Supplementary Methods.
Statistical Analysis
Values are expressed as mean ± standard deviation. The Student t-test was used to detect
differences in comparisons involving only 2 groups. Data between the 4 subject groups were
analyzed by analysis of variance. For some variables (caspase, NF-kB p65 and miR-31 levels),
a logarithmic transformation was performed to minimize the effects of heteroscedasticity.
Differences among the groups were assessed using the Tukey-HSD post hoc t-test for multiple
comparisons. Statistical tests were two-sided and were considered significant at P< .05.
Statistical analysis was performed using R (http://www.R-project.org).
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Results
Establishment of a Rat Esophageal Neoplasia Model Overexpressing miR-31
Previously (12) we examined the effect of long-term ZD (23 weeks) on miRNA expression in eight
rat tissues by nanoString miRNA profiling assay, and miR-31 overexpression was documented in
esophagus and two other stratified squamous epithelial tissues (tongue and skin) and in peripheral
blood mononuclear cells. To establish an in vivo esophageal neoplasia model overexpressing miR31 for examining conditions that lead to human ESCC initiation, we determined if short-term ZD (5weeks) that produces a hyperplastic esophageal phenotype with a proinflammation gene signature
(11) induces miR-31 upregulation as does long-term ZD (12). For this, we performed an arraybased miRNA expression profiling (27) of esophageal mucosa from weanling rats fed ZD or Znsufficient (ZS) diet for 5 weeks (n=4/dietary group). Fourteen dysregulated miRNAs were identified
in ZD esophagus (q-value <10% [q-value is the minimum false discovery rate (FDR) at which the
test may be called significant], Supplementary Table 1). Notably, miR-31 was the most upregulated
species (ZD vs ZS = 10-fold upregulation, q value=0%). This finding was verified by quantitative
PCR (qPCR) (Figure 1A) and northern analyses (Figure 1B), using RNA samples from ZD and ZS
esophagus (n=8 rats per group). Using the same RNA assessment methods, we found that 5
weeks after ZD rats were switched to a ZS diet, the ZD-induced miR-31 overexpression was
returned to normal ZS level (ZR/5wk rats; Figure 1, A and B). Thus, miR-31 expression is
responsive to Zn treatment, establishing a short-term ZD esophageal preneoplasia model for study
of effects of miR-31 overexpression and silencing.
In Vivo Anti-miR-31 Delivery in Zn-Deficient Rat Esophageal Preneoplasia Model
LNA-modified oligonucleotides are a class of RNA that exhibits in vivo high biostability, low toxicity,
and adequate biodistribution (28). LNA-anti-miR-122 oligos were shown to mediate effective in vivo
inhibition of liver-expressed miR-122 function in rodents (29) and nonhuman primates (30). In a
phase 2a clinical trial to treat patients with hepatitis C virus (HCV) infection, miravirsen (an LNA-
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modified inhibitor of miR-122) showed dose-dependent reductions in HCV RNA levels, thus
demonstrating a therapeutic effect by targeting a host miRNA (31).
To inhibit esophageal miR-31 expression in vivo in Zn-deficient rats, we used LNA-anti-miR-31
oligonucleotide (complementary to nt 1-22 in the mature miR-31 sequence, hereafter called antimiR). As depicted in Figure 1C, male weanling rats received a ZD or ZS diet and were randomized
into 4 groups: ZD/anti-miR, ZD/LNA-scrambled, ZD/saline, and ZS/saline. The animals received 10
doses of anti-miR, scrambled oligos, or saline, over a period of 5-weeks. During the 5-week study,
the growth rate of all ZD groups was comparable to pair-fed ZS rats (Figure 1E). Regardless of
treatment, serum Zn level in the three ZD groups was similar (~50 μg/100 ml), but lower than in ZS
rats (P < .001, Figure 1D).
After 5 weeks of ZD diet, qPCR analysis (Figure 1F) showed that ZD controls had markedly
higher miR-31 levels in esophagus, tongue, and circulating blood (P = .009 to < .001) than the ZS
counterpart, a result consistent with long-term ZD (23 weeks) (12). Importantly, anti-miR-31
treatment resulted in ~60% inhibition of miR-31 expression in the three tissues vs counterpart ZD
controls (Figure 1F. Esophagus: ZD/anti-miR vs ZD/scrambled, P = .002. Tongue: ZD/anti-miR vs
ZD/scrambled, P < .001. Blood: ZD/anti-miR vs ZD/scrambled P < .001). The qPCR findings were
confirmed at the cellular level by in situ detection of miR-31 in FFPE esophageal/lingual tissues. As
shown in Figure 1G (esophagus) and Figure 2A (tongue), anti-miR-31 treatment resulted in an
overall reduction in the scope and intensity of miR-31 signal in ZD/antimiR esophageal/lingual
epithelia vs ZD controls (n=10 rats/cohort). Thus, despite continued dietary Zn-deficiency, antimiR-31 delivery effectively inhibited ZD-induced miR-31 expression in the esophagus/tongue.
Macroscopically, anti-miR treated ZD esophageal epithelia were strikingly less swollen than
control ZD esophagi. Histologically, the ZD/anti-miR cohort showed a markedly thinned epithelium
with fewer cell layers than the hyperplastic ZD/scrambled cohort (Figure 3A). These findings
demonstrate that miR-31 inhibition prevented the development of a hyperplastic esophageal
phenotype in rats in spite of their ZD diet.
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In addition to the esophagus, anti-miR-31 treatment prevented the development of a ZDinduced hyperplastic tongue epithelium (32), as evidenced by a thinned epithelium (Figure 2B).
Moreover, throughout the 5-week study period, anti-miR-treated ZD rats showed a near normal
hair coat while ZD/saline or ZD/scrambled rats typically developed a poor coat with alopecia.
Because ZD induces miR-31 expression in squamous skin associated with an inflammatory
phenotype (12), it is likely that the improved skin phenotype in ZD rats was due to inhibition of miR31 by anti-miR in skin, as in esophagus, tongue, and blood (Figure 1F).
miR-31 Antagonism and Esophageal Cellular Proliferation and Apoptosis
To assess esophageal cellular proliferation, we employed the proliferative marker PCNA.
Immunohistochemical (IHC) analysis showed that the cell proliferation index (% of intensely
stained PCNA-positive nuclei, expressed as mean ± standard deviation, n=10 samples/group) in
the ZD/anti-miR esophagus (27±5.1%) was markedly reduced (P < .001) relative to control
ZD/saline (48±7.3%) or ZD/scrambled esophagus (47±4.2%) (Figure 3B). Similarly, immunoblot
analysis showed reduced PCNA expression in ZD/anti-miR esophagi (Figure 3C) as well as in
ZD/anti-miR tongue (Figure 2C) relative to ZD controls. Thus, miR-31 inhibition led to prominently
decreased cellular proliferation.
To assess apoptosis induction, a luciferase-based chemical assay was used. ZD/anti-miR
esophagus showed statistically significantly higher caspase 3/7 (P = .005, fold change = 10.7) and
caspase 9 activities (P = .019, fold change = 3.8) than ZD/saline esophagus (Figure 3D), indicating
that miR-31 inhibition induced apoptosis. Together, the data indicate that miR-31 inhibition
suppresses the hyperplastic ZD esophageal phenotype via reduction of cell proliferation and
activation of apoptosis.
Identification of Physiological miR-31 Targets in Esophageal Neoplasia
To identify genes with altered transcript levels in response to miR-31 silencing in vivo, we
performed genome-wide expression profiling of esophageal mucosa from the 4 animal groups at

10

48 h after the final LNA-antimiR dose (Supplementary Table 2), using Affymetrix Rat Genome 230
2.0 GeneChip (n=5 rats/treatment group). Hierarchical clustering of mRNA profiles revealed that
the expression pattern in ZD/anti-miR esophagus was different from the control ZD/scrambled and
ZD/saline esophagus, which were similar but distinct from ZS/saline esophagus (Figure 3E),
implying that a large pool of the upregulated mRNAs in ZD/anti-miR RNAs correspond to
derepressed miR-31 targets (29). Analysis of the array data revealed that the list of derepressed
genes in ZD/anti-miR vs ZD/saline esophagus and in ZD/anti-miR vs ZD/scrambled esophagus
were similar. In addition, the list of differentially expressed genes were similar in ZD/scrambled vs
ZS/saline and in ZD/saline vs ZS/saline, indicating that LNA/scrambled had little effect on gene
expression. Guided by miR-31 target prediction bioinformatics, 13 derepressed genes (Figure 3F)
were chosen from the intersection analysis between a joint set of genes from ZD vs ZS rats and
that from ZD vs ZD/anti-miR group. To validate this prediction, qPCR analysis was
performed (Figure 3G). Of the 10 genes that showed derepression with anti-miR
treatment, six genes, including Stk40 (P < .001), Cpm (P = .02), Acta2 (P = .02), Ces1d (P = .004),
Ly6e (P = .01), and Sft2d2 (P = .03) achieved a statistically significant difference between ZD/antimiR and ZD controls (Figure 3G), thereby validating the bioinformatics prediction (Figure 3F) that
such genes would be derepressed after miR-31 silencing.
Stk40 (33, 34) and Cpm (35) are of particular interest because of their roles in inflammation.
We then determined if miR-31 directly interacts with Stk40 3’UTR by cotransfecting a pGL3 3¢ UTR
luciferase reporter vector with synthetic miR-31 (Figure 4, A-C). A two-fold decrease in luciferase
activity was observed, indicating a direct interaction between the miRNA and Stk40 3¢ UTR. Target
gene repression was rescued by deletions in the complementary seed sites (fold change = 1.7,
Figure 4C). These data establish that Stk40, a known negative regulator of NF-kB mediated
transcription (33), is a miR-31 direct target. The regulation of Stk40 by miR-31 has been reported
in ovarian cancer cells (21) and primary keratinocytes in psoriasis (34). Additionally, we
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demonstrated that the Cpm 3’ UTR is a miR-31 direct target by using the 3¢ UTR luciferase
reporter assay (Figure 5A). We showed by western blot that CPM protein was downregulated in
hyperplastic ZD esophagus that overexpresses miR-31, and was restored upon miR-31 inhibition
(Figure 5B). Although CPM has emerged as a potential cancer biomarker (35), the mechanism by
which CPM contributes to carcinogenesis remains to be determined.
Anti-miR-31 Effects on STK40-NF-kB Based Inflammatory Pathway
We next focused our study on Stk40 because of its role in regulation of NF-kB (33), a key mediator
of inflammation (36). The ZD-induced esophageal preneoplasia is accompanied by cytoplasmic
NF-kB p65 overexpression and nuclear translocation of NF-kB phospho-p65 (37). We showed by
enzyme-linked immunosorbent assay (ELISA) that miR-31 inhibition led to statistically significantly
lower NF-kB p65 levels in ZD/anti-miR esophageal lysates as compared with control ZD lysates (P
= .002, fold change = -2.8, Figure 4E), a result confirming that miR-31 inhibition suppresses NF-kB
activity (34). To determine whether a connection occurs among miR-31, STK40, and downstream
NF-kB signaling in esophageal neoplasia, we performed in situ detection of miR-31 expression
combined with IHC analysis of the NF-kB p65-RAGE-S100A9 pathway (11), using FFPE
esophageal tissues. In hyperplastic ZD/scrambled esophagus (Figure 4F), miR-31 overexpression
was associated with downregulation of STK40 protein and accompanying upregulation of the NFkB p65-RAGE-S100A9 inflammatory pathway. Remarkably, in vivo anti-miR-31 delivery reduced
miR-31 expression, upregulated STK40 protein expression, and abolished this NF-kB p65-RAGE
inflammation network, resulting in a non-inflammatory esophageal phenotype that resembles the
Zn-sufficient esophagus (Figure 4F). These in vivo findings show for the first time the important
connections between oncomiR-31, STK40, and NF-kB p65-controlled signaling in esophageal
neoplasia.
Cellular Localization of miR-31 Expression in Human ESCC Tissue
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The cellular origins of miRNAs are of importance in the understanding of the mechanistic roles
of miRNAs in tumor development. In order to determine the cellular localization of miR-31 in
human ESCC, we evaluated miR-31 expression in archived FFPE human ESCC tissues by ISH
(n=12 cases). Consistent with our previous study on miR-31 ISH in ESCC from carcinogentreated ZD rats (12), all 12 cases of human ESCCs showed an intense and abundant miR-31
ISH signal in the tumor tissues and a moderate miR-31 signal in the adjacent esophageal
mucosa (Figure 6). These results represent the first in situ detection of miR-31 in human ESCC,
thereby providing support for miR-31 as a potential prognostic and/or therapeutic marker for
ESCC.
Overexpression of miR-31 and STK40 and NF-kB Expression in Human ESCC Cells
To define the role of STK40 in human ESCC cells, we analyzed cell proliferation and apoptosis
after STK40 silencing. STK40 silencing, as shown by western blot, decreased caspase 3/7 activity
(P = .015) and increased viability of esophageal cancer cells (P = .03) (Figure 4D). These results
are consistent with the cell proliferation (Figure 3B) and apoptosis (Figure 3D) data in ZD rat
esophagus that documented miR-31 overexpression with accompanying STK40 downregulation
(Figure 4F). Next the expression of miR-31, STK40, RELA, and NF-kB1 were analyzed by qPCR in
six human ESCC cell lines of the KYSE-series (22) (KYSE-450, -410, -520, -510, -180, -270)
(Figure 4G). miR-31 was overexpressed in all six ESCC cell lines vs human normal esophagus cell
line HET-1A. In four cell lines (KYSE-450, -410, -520, and -510), miR-31 overexpression was
accompanied by low STK40 expression and an inverse relationship between STK40 and
RELA/NF-kB1. These data document, for the first time, the important connections among
oncomiR-31, STK40, and NF-kB in human ESCC cells.
Activation of miR-31 Promoter Region in Zn-Deficient Esophagus
Finally, to elucidate the mechanisms by which miR-31 is upregulated by Zn-deficiency, we
performed chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) on
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esophagi from Zn-modulated rats (ZD, ZR, ZS). This analysis used antibodies for chromatin
modification marks H3 lysine 4 trimethylation (H3K4me3), H3 lysine 4 monomethylation
(H3K4me1), and H3 lysine 27 trimethylation (H3K27me3). Enrichment of H3K4me3 binding signals
indicates the presence of a promoter region, whereas those of H3K4me1 and H3K27me3
represent marks for enhancers and repressed regions, respectively (38)
To identify enriched regions of histone modifications in ChIP-seq data, we performed peakcalling analysis using SICER algorithm (24) (Supplementary Methods). By analyzing the genome
occupancy of H3K4me3, we identified a promoter region ~30 kb (kilobases) upstream of the
mature sequence location of miR-31 (Figure 7A). We used Integrative Genomics Viewer (IGV) (39)
to visualize the promoter region of miR-31. H3K4me3 binding signals were statistically significantly
enriched in ZD vs ZS esophagus (P < .001, Figure 7B), indicating that the promoter is activated in
ZD esophagus. With Zn-replenishment, H3K4me3 levels were significantly reduced (ZD vs ZS =
2.58 as compared to ZR vs ZS=1.52, Figure 7B), accompanied by a near normal miR-31 level
(northern blot, Figure 1B and ISH, Figure 7C) and esophageal phenotype (Figure 7C). On the
other hand, the histone mark for enhancer H3K4me1 binding signals were minimally enriched in
ZD esophagus and no enriched locations were found for repressor H3K27m3 binding signals
(Supplementary Figure 2; Supplementary Table 3).
This miR-31 promoter region is conserved in humans and rats (Supplementary Figure 1). To
test the presence of putative cis-regulatory elements (promoters, enhancers) in human, we used
public ChIP-seq data of several human cell lines and identified binding sites of PolII in the CpG
island corresponding to rat island 77. Using chromatin state dynamics from ENCODE chromatic
portal (40), we determined that this region is characterized by the presence of poised or active
promoters (Supplementary Figure 1A). Because a genome map of cis-regulatory elements is not
available in rat genome, we used Blat, the University of California, Santa Cruz (UCSC) Genome
Browser (41) to find a conserved region in rats similar to CpG island 77. Using Blat
(Supplementary Methods), we found a region with 85.2% similarity with humans. This region is
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indeed the promoter region that we have identified in rats (ChIP-seq data, Supplementary Figure
1B).
Identification of RelA and Sp1 in miR-31 Promoter Region
We downloaded the DNA sequence from the rat genome (rn4) located at chr5: 108.520.153108.537.803 that showed the highest continuous peak enriched in ZD esophagus for chromatin
mark H3K4me3. To find the Transcription Factor Binding Site (TFBs), we used Jaspar Core (25)
and TRANSFAC database (26) and identified one predicted RelA (p65 subunit of NF-kB) binding
site: GGGAATTCCCC (5:108,526,856-108,526,866 [+]) and one TFBs for Sp1:
GGACGCCCCGCCCCGGCCCCGCCCCGACGG (5:108,527,171-108,527,194 [+]). These
sequences are both located within the miR-31 promoter region (Figure 7A). The TFBs for rat NFkB p65 (subunit of NF-kB transcription factor complex) is located 2 kb downstream of the CpG
island 94 (Figure 7A). We cloned this sequence of ~400 bp in a promoterless vector (PGL3basic)
and cotransfected this construct along with a NF-kB p65 siRNA or a dominant active (DA) I-kBa in
293T cells. NF-kB p65 knockdown or inhibition resulted in a greater than two-fold decrease in miR31 promoter activity, suggesting that this microRNA is transcriptionally regulated by NF-kB p65
(Figure 7D). Sp1 is located within the CpG island of the miR-31 promoter (Figure 7A) and was
validated through electrophoretic mobility shift assay (Figure 7E). These findings indicate that the
putative promoter region may be bound by NF-kB transcription factor complex together with the
Sp1 transcription factor.

Discussion
ESCC is a lethal cancer due to diagnosis at advanced stage and lack of effective therapies. In
comparison with other human cancers, ESCCs exhibit few expression changes in microRNAs and
no bona fide physiological targets. miR-31 acts as an oncomiR in ESCC (13, 14) (Figure 6), and
tongue SCC (18) (12). Its biological functions in these cancers, however, have not been defined
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and its potential as a therapeutic target not assessed. Our rat model that recapitulates features of
human ESCC, including Zn-deficiency, miR-31 overexpression, and inflammation (8, 13, 14, 42)
provides an opportunity to decipher the mechanism of oncomiR-31 function in ESCC and its
relationship to ESCC promotion by dietary Zn deficiency. Using this model, the current study
shows that in vivo miR-31 antagonism by systemically administered LNA-anti-miR decreased miR31 overexpression in esophagus/tongue and circulating blood and prevented the development of a
preneoplastic phenotype in esophagus and tongue in ZD rats. Importantly, we show that systemic
delivery of anti-miR-31 reduces cellular proliferation, activates apoptosis, and represses the miR31 associated STK40-NF-kB based inflammation signaling in the esophagus. Thereby, the
tumorigenic effects of Zn-deficiency are overcome and esophageal neoplasia inhibited. These data
are the first evidence that in vivo anti-miR-31 delivery exerts multiple anticancer activities and
inhibits ESCC neoplasia.
To pinpoint biologically significant miR-31 targets from the hundreds of putative targets
generated by target prediction algorithms (43), our approach has led to identification of Stk40 as a
biological miR-31 target by using in vivo miR-31 antagonism and microarray analysis of
derepressed genes. Although Stk40 was identified as a miR-31 direct target in ovarian cancer cell
lines (21) and psoriasis (34) and Stk40 is a known negative regulator of NF-kB signaling, the
important connections between miR-31, Stk40, and NF-kB signaling has not been demonstrated in
human cancers. Our study shows for the first time that systemic delivery of anti-miR-31
suppresses the esophageal neoplasia by derepressing its target, Stk40, and inhibiting the
associated STK40-NF-kB controlled inflammatory pathway. Because the same connections among
miR-31, Stk40, and NF-kB signaling is also shown in human ESCC cell lines, our in vivo results
provide a mechanistic rationale for clinical development of miR-31 as a biomarker and treatment
target for ESCC patients.
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Transcription factors are known to regulate miRNA expression in a tissue- and disease-specific
manner (44). By performing ChIP-seq on esophagi from Zn-modulated rats using an antibody for
chromatin modification mark, H3K4me3 that detects promoters (45), our analysis identified a miR31 promoter region activated in ZD esophagus. Dietary Zn-replenishment restored the regulation of
this genomic region to the inactive state, miR-31 levels, and the hyperplastic esophageal
phenotype to near normal. These data provide the first evidence that miR-31 promoter activity is
regulated by dietary Zn. In addition, our motif-finding analysis demonstrates the presence of an
NF-kB binding site in the miR-31 promoter region. NF-kB p65 knockdown resulted in a decrease in
miR-31 promoter activity, indicative of transcriptional regulation of miR-31 by NF-kB p65.
Together, these data define a mechanism whereby Zn-deficiency upregulates miR-31 by activating
its promoter/TFBs and unleashing miR-31-associated STK40-NF-kB controlled inflammatory
signaling to produce a preneoplastic phenotype.
A limitation of this study is the fact that the endpoint was the early hyperplastic and
inflammatory esophageal phenotype rather than esophageal cancer itself. Studies are in progress
to specifically address this issue.
In summary, our in vivo work defines the signal pathway underlying the interaction of Zndeficiency and miR-31 overexpression in promoting esophageal neoplasia (Figure 8). OncomiR-31
is a critical target involved in ESCC pathogenesis. Antagonism of miR-31 leads to suppression of
esophageal neoplasia, thereby providing support for clinical development of miR-31 as a
biomarker and therapeutic target for this deadly disease.
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Figure Legends
Figure 1. Systemic delivery of locked-nucleic-acid mediated anti-miR-31 in Zn-deficient (ZD) rat
esophageal preneoplasia model. A) qPCR analysis of esophageal miR-31 expression in Znmodulated rats, using rat snoRNA as the normalizer (n = 8 rats/group, ‡P < .001, Tukey-HSD post
hoc unpaired t-test for multiple comparisons. Error bars represent standard deviation). B) Northern
analysis of esophageal miR-31 expression in Zn-modulated rats (n = 5-8 rats/group). C-G)
Systemic delivery of anti-miR-31 to ZD rats. C) Study design. D) Serum Zn levels are similar
among ZD groups but statistically significantly lower than Zn-sufficient (ZS) rats (n = 12-20/group,
‡

P < .001. Error bars represent standard deviation). E) Growth curves are similar in all 4 animal

groups. Error bars represent standard deviation. F) qPCR analysis of miR-31 expression in
esophagus, tongue, and blood in 4 animal groups, using rat snoRNA as the normalizer (n = 12-20
rats/group. Esophagus: ZD/saline vs ZS/saline (‡P < .001), ZD/scrambled vs ZS/saline (‡P < .001),
ZD/anti-miR vs ZD/saline (†P = .004), and ZD/anti-miR vs ZD/scrambled (†P = .002). Tongue:
ZD/saline vs ZS/saline (†P = .002), ZD/scrambled vs ZS/saline (†P = .001), ZD/anti-miR vs
ZD/saline (‡P < .001) and ZD/anti-miR vs ZD/scrambled (‡P < .001). Blood: ZD/saline vs ZS/saline
(†P = .009), ZD/anti-miR vs ZD/saline (‡P < .001) and ZD/anti-miR vs ZD/scrambled (‡P < .001).
Error bars represent standard deviation). G) In situ hybridization (ISH) analysis shows
moderate/infrequent miR-31 signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′indolylphosphate); counterstained by nuclear fast red) in ZD/anti-miR and ZS/saline esophagus,
but strong/abundant miR-31 signal in hyperplastic ZD controls. No ISH signal was seen with mmmiR-31 (two mismatches). Scale bars: left, 100 μm; right, 25 μm. Open rectangles are insets
shown in panels to the right. All statistical tests were two-sided.
Figure 2. Anti-miR-31 effects on Zn-deficient (ZD) rat lingual preneoplasia. A) In situ hybridization
(ISH) analysis of miR-31 expression. miR-31 signal (blue, 4-nitro-blue tetrazolium and 5-brom-4chloro-3′-indolylphosphate) is moderate/infrequent in ZD/anti-miR tongue but strong/abundant in
hyperplastic ZD controls. Scale bars: left, 100 μm; right, 25 μm. Open rectangles are insets shown
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in panels to the right. B) Hematoxylin and eosin (H&E) staining showing a thinned ZD/anti-miR
lingual epithelium vs hyperplastic ZD control tongue; immunohistochemical showing few PCNApositive nuclei (red, 3-amino-9-ethylcarbazole substrate-chromogen,) in thinned ZD/anti-miR
tongue vs abundant PCNA-positive nuclei in proliferative ZD/scrambled control (H&E, Scale bar,
100 μm. PCNA, Scale bar, 100 μm; left 25 μm). Open rectangles are insets shown in panels to the
right. C) Immunoblot analysis shows reduced PCNA expression in tongue following systemic
delivery of anti-miR-31.
Figure 3. Anti-miR-31 effects on Zn-deficient (ZD) rat esophageal preneoplasia and potential miR31 targets. A) Histology of ZD/anti-miR vs ZD/scrambled esophagus (hematoxylin and eosin-stain,
Scale bar, 100 μm). B) Immunohistochemical analysis shows few PCNA-positive nuclei (red, 3amino-9-ethylcarbazole substrate-chromogen) in thinned ZD/anti-miR esophagus vs abundant
PCNA-positive nuclei in proliferative ZD controls (Scale bars: left, 100 μm; right, 25 μm). Open
rectangles are insets shown in panels to the right. C) Immunoblot analysis shows reduced PCNA
expression in esophagus following systemic delivery of anti-miR-31. D) Luminescent assays show
caspase 3/7 and caspase 9 activities in the 4 animal groups (RLU=relative light units, n = 5-8
rats/group. Caspase 3/7, †P = .005. Caspase 9, *P = .019, Tukey-HSD post hoc t-test. Error bars
represent standard deviation). E) Unsupervised hierarchical cluster of the most significant genes
(upregulated genes, red; downregulated genes, green) in rat esophagi from the 4 animal groups
(Figure 1C). F) Barplot graph showing expression of 13 predicted miR-31 targets in ZD esophagus
that were derepressed after anti-miR treatment. G) qPCR analysis of the predicted genes, using
OAZ1 as normalizer (n = 8-12 rats/ group. Error bars represent standard deviation. Tukey’s
multiple comparison test. Stk40: ZD/anti-miR vs ZD/saline, ZD/anti-miR vs ZD/scramble, ‡P < .001.
Cpm: ZD/anti-miR vs ZD/saline, ZD/anti-miR vs ZD/scramble, *P = .02. Acta2: ZD/anti-miR vs
ZD/saline, *P = .02; Ces1d, ZD/anti-miR vs ZD/saline, †P = .004; Ly6e: ZD/anti-miR vs ZD/saline,
*P = .01; Sft2d2: ZD/anti-miR vs ZD/saline, *P = .03). All statistical tests were two-sided.
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Figure 4. Anti-miR-31 effects on Stk40 – NF-kB based inflammatory signaling. A-C) Stk40 3’ UTR
is a miR-31 direct target. A) Stk40 3’UTR presents two miR-31 binding sites. B) Alignment of miR31 seed region with Stk40 3’UTR. Sites of target mutagenesis are indicated (- = deleted
nucleotides). C) Luciferase reporter assays indicates direct interactions between miR-31 and
Stk40. Error bars represent standard deviation. ‡P < .001. D). STK40 silencing affects proliferation
and apoptosis of esophageal squamous carcinoma (ESCC) cells. Western blot showing STK40
downregulation in KYSE-70 ESCC cells after transfection with STK40 siRNA; cell proliferation
assay showing increased cell survival (*P = .03, error bars represent standard deviation) and
luminescent assays showing decreased caspase 3/7 activity after STK40 silencing (*P = .015,
error bars represent standard deviation). E) Enzyme-linked immunosorbent assay shows NF-kB
p65 expression was statistically significantly reduced in Zn-deficient (ZD)/anti-miR vs control ZD
cohorts (n=6-8 rats/group, Tukey-HSD post hoc unpaired t-test, †P = .002. Error bars represent
standard deviation). F) In situ hybridization (ISH) analysis of miR-31 expression;
immunohistochemical analysis of STK40, NF-kB p65, RAGE, S100A8, and S100A9 expression in
esophageal formalin-fixed paraffin-embedded sections. ZD/anti-miR (middle) and ZS (right)
esophagi showing weak/diffuse miR-31 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4chloro-3′-indolylphosphate); strong cytoplasmic STK40 (brown, 3,3′-diaminobenzidine
tetrahydrochloride [DAB]) but weak cytoplasmic NF-kB p65, RAGE (brown, DAB), and S100A8/A9
(red, 3-amino-9-ethylcarbazole substrate-chromogen) immunostaining. In contrast, hyperplastic
ZD/scrambled esophagus (left) showing strong/abundant miR-31 ISH signal, weak/diffuse
cytoplasmic STK40 immunostaining, but strong cytoplasmic immunostaining of NF-kB p65, RAGE,
and S100A8/A9 protein. (Scale bar, 25 μm). G) qPCR analysis of miR-31, STK40, RELA, and NFkB1 expression in 6 human esophageal squamous cell carcinoma (ESCC) cell lines and control
esophageal squamous epithelial cells HET-1A, using RNU44 and OAZ1 and as normalizer for
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miR-31 and mRNA, respectively. qPCR analysis was performed in triplicate. All statistical tests
were two-sided.
Figure 5. Cpm as a miR-31 direct target. A) Luciferase report assay showing direct interaction
between miR-31 and Cpm. Inactivation of miR-31 binding site by site-direct mutagenesis rescues
luciferase activity (experiments were performed three times. ‡P < .001, error bars, ± standard
deviation). All statistical tests were two-sided. B) Western blot showing increase in CPM protein
expression in Zn-deficient (ZD)/antimiR esophageal lysates relative to control ZD samples.
Figure 6. Localization of miR-31 in human esophageal squamous cell carcinoma (ESCC) tissue by
in situ hybridization (ISH). Representative sections of ESCC tissues are shown (hematoxylin &
eosin [H&E]-stain). miR-31 ISH signal (blue, 4-nitro-blue tetrazolium and 5-brom-4-chloro-3′indolylphosphate; counterstain, nuclear fast red) was intense and abundant in near serial formalinfixed paraffin-embedded sections of ESCC tumor tissue but moderate in adjacent non-tumorus
esophageal mucosa (Case 2). No ISH signal was obtained with mismatched mm-miR-31 (2
mismatches). Open rectangles are insets illustrated in panels directly below. Scale bars: 100 µm
(H&E, miR-31, and mm-miR-31); 25 µm (miR-31 inset).
Figure 7. ChIP-seq identification of the promoter region of miR-31 and TFBs. A) Integrative
Genomics Viewer view shows the putative miR-31 promoter region in Zn-deficient (ZD) rat
esophagus: miR-31 (red arrow), CpG island (red box), and TFBs NF-kB/Sp1 (blue box). The
values on the y-axis for ChIP-seq data are input normalized intensities; the values on red barplots
are normalized read counts/library size x 1,000,000. B) Table shows differentially enriched regions
(H3K4me3) among Zn-modulated groups (Zn-sufficient = ZS, Zn-replenished = ZR). C)
Hematoxylin and eosin-stain analysis of histology, in situ hybridization analysis of miR-31
expression, and immunohistochemical analysis of the proliferation marker PCNA of Zn-modulated
esophagus (scale bars, 25 μm). D) NF-kB transcriptionally activates miR-31. Luciferase
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experiment shows downregulation of miR-31 promoter activity after NF-kB silencing (siRELA) or
the overexpression of a NF-kB dominant active inhibitor (DAIKB) (experiments were performed
three times. ‡P < .001, error bars, ± standard deviation). All statistical tests were two-sided. E)
DNA mobility shift assay shows the binding of Sp1 to Sp1-probe motive. Lane 1: labeled Sp1motive probe. Lane 2: two complexes at different molecular weights (shift 1, shift 2) are formed by
the addition of nuclear extracts from HELA cells to Sp1-motive probe. Lane 3: anti-Sp1 antibody
disrupts the higher molecular weight complex (shift 2).
Figure 8. Molecular pathway underlying interaction of Zn-deficiency and miR-31 overexpression in
promoting esophageal preneoplasia. Zn-deficiency induces miR-31 overexpression leading to
downregulation of its direct target Stk40. Stk40 downregulation activates NF-kB and Rage through
S100a8/a9 dimer protein complex, thereby promoting inflammation and cellular proliferation to
produce the preneoplastic esophageal phenotype.
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